Novartis

Novartis, a pharmaceutical preparation manufacturer headquartered in CH, has reported significant greenhouse gas emissions. For the year 2025, the company's total emissions were approximately 4.38 billion kg CO2e. This total comprises about 192.3 million kg CO2e from Scope 1 emissions, and approximately 14.9 million kg CO2e from Scope 2 emissions (market-based). Scope 3 emissions constituted the largest portion, totalling around 4.17 billion kg CO2e, with purchased goods and services being a significant contributor within this scope.

In 2024, Novartis's total emissions were approximately 4.52 billion kg CO2e, with Scope 1 emissions at about 210.6 million kg CO2e, Scope 2 emissions at around 29.8 million kg CO2e (market-based), and Scope 3 emissions at approximately 4.28 billion kg CO2e.

The company has established ambitious climate commitments. Novartis aims to be carbon neutral in its own operations (Scope 1 and 2) by 2025. Furthermore, it has set a target to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2030 from a 2022 base year, and absolute Scope 3 GHG emissions by 42% within the same timeframe. Looking further ahead, Novartis is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2040. This long-term goal includes maintaining at least a 90% absolute reduction in Scope 1 and 2 emissions from 2030 through 2040, and a 90% absolute reduction in Scope 3 emissions by 2040, all from a 2022 base year.

Novartis has also committed to the Science Based Targets initiative (SBTi), aligning its targets with the goal of limiting global warming to 1.5°C. Their SBTi-approved targets include a commitment to reduce absolute Scope 1, 2, and 3 GHG emissions by 35% by 2030 from a 2016 base year.